RxDoctor Payments Data

Robin Pursifull

Family · Minot, NDNPI 1245824838

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 41.7% of the total. 2025 is the largest year on record at $527, 3.3 times the $159 reported in 2022.

$1,460in general payments, 2019–2025

Across 88 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$609
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$412
  • Alkermes, Inc.$117
  • Otsuka America Pharmaceutical, Inc.$105
  • Axsome Therapeutics, Inc.$62
  • Lundbeck LLC$59
  • plus $96 from 4 others

What the payments were for

  • Food & beverage$1,460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,460 in reported general payments places this provider in the 85th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$12,473
Medicare patients
75
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$20,629
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine53$1,824
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen46$1,132
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$925
Pregabalin18$824
Gabapentin58$724
Bupropion XlBupropion Hcl15$395
Oxycodone Hcl16$284
Lamotrigine13$228
Duloxetine Hcl15$219
Zolpidem Tartrate40$173
Trazodone Hcl14$169
Quetiapine Fumarate17$151
Alprazolam25$109
Escitalopram Oxalate18$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$609$20,62915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 family providers in North Dakota.

Other family in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →